AI pioneer Innoplexus and phytopharmaceutical company DrD are partnering toRead More
Partnering to unlock the true potential of cannabis in medical care
Innoplexus @ Machine Intelligence Summit, Berlin 2017
Innoplexus AG proudly announces that our founder and CEO, Dr Gunjan Bhardwaj will be on the panel discussion at Machine Intelligence Summit to be held on 14th July 2017, in Berlin, Germany.
The panel discussion is around “From Past Learning to Predictive Future” at 13:45 CET on Friday at Deutsche Telekom Hauptstadtrepräsentanz Französische Straße 33a-c, 10117 Berlin. The other participants on the panel are Prof. Christoph von der Malsburg, Barbara Pogorzelska, Josh Chen.
The discussion is on how machine intelligence is used to accomplish the tasks on reducing efforts and complexity in understanding the data sets to recognise the patterns and to predict future behaviours. The panel of cross industry experts shall discuss use cases where machine intelligence predictions have real impact.
Other team members from Innoplexus who are going to be present at the event are:
- Mr. Gaurav Tripathi, Co-founder and CTO
- Ms Varsha Rohani, Senior Manager, Corporate Development
- Mr Yannik Schelske, Data Scientist
- Mr. Tanay Gahlot, Software Engineer working in our Deep Learning team
If you are in Berlin on 14th July, please do drop by to listen to our views on AI, Deep Learning and Machine Learning, and to meet our amazing team members.
About the Event
Machine Intelligence Summit, organised by SearchInk, gathers some of the most brilliant minds in the field of Artificial Intelligence to discuss the stakes of Deep Learning and Machine Intelligence.
About Innoplexus
Innoplexus caters to Life sciences industry offering Data as a Service (DaaS) and Continuous Analytics as a Service (CAaaS) products. We leverage Artificial Intelligence and advanced analytics to help reduce the drug development time from synthesis to approval, significantly.
We use proprietary algorithms and technologies to help global Life Sciences and Pharmaceutical organisations across all stages (Pre-clinical, clinical, regulatory and commercial) of drug development.
We automate the collection, curation, aggregation and analysis, of billions of data points from thousands of data sources, using machine learning, network analysis, ontologies, computer vision and entity normalisation.
Featured News
Strategic partnership announcement: Innoplexus holding company Partex NV is pleased
Exciting News! Anavex Life Sciences and Partex NV Announce Strategic Partnership to Enhance Patient Experience.Anavex Life Sciences Corp. and Partex NV N.V. Group are pleased to announce…
AI supports targeted therapy recommendations fortumor diseases – BMBF funds
The treatment and support of patients with advanced tumor diseases is a complex task involving numerous disciplines. For the interdisciplinary…
Innoplexus and Innovatrix capital partner to bring about new risk-transfer
Artificial Intelligence (AI) pioneer Innoplexus and London based Parametric Insurance start-up, Innovatrix Capital, collaborating upon using AI & Machine Learning…
Innoplexus and Inflection Biosciences enter strategic collaboration based on Artificial
Innoplexus and Inflection Biosciences enter strategic collaboration based on Artificial Intelligence to expedite PIM kinase inhibitor development ESCHBORN, Germany, May 30,…
Parexel and Innoplexus Unveil Single Source of COVID-19 Information for
COVID-19 Clearinghouse enables direct access to latest COVID-19 datasets, publications, research and clinical trialsBOSTON and DURHAM, N.C. and ESCHBORN, Germany,…
New app for cancer patients
Das Eschborner Unternehmen Innoplexus hat eine neue App namens „Curia“ für Krebspatienten veröffentlicht. Mit dem Computerprogramm, das sich unentgeltlich herunterladen…
Innoplexus wins Silver Edison Award for OntosightⓇ Explore
Frankfurt, Germany, March 26, 2020 — Innoplexus AG has been honored with the Silver Edison Award 2020 for its proprietary…
AI CTP engine estimated failure for Biogen’s aducanumab
While drug development can be incredibly lucrative, it is a very risky business. German company Innoplexus has developed a domain-specific…
How can AI be leveraged for Clinical Trial Prediction?
Successful clinical trials occur at a ratio of 1 in 10, costing around $2-$3 billion, with drugs taking 10–12 years…
Innoplexus launches new Blockchain platform for Pharma innovation
If your loved one was diagnosed with a potentially fatal illness, wouldn’t you want all the information possible to be…